Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis

BACKGROUND AND AIM: Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD). Till now, few papers regarding on-treatment hepatic decompensation have been reported. The study aims to analyze the general...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Yi-Chung, Jeng, Wen-Juei, Huang, Chien-Hao, Teng, Wei, Chen, Wei-Ting, Chen, Yi-Cheng, Lin, Shi-Ming, Tai, Dar-In, Lin, Chun-Yen, Sheen, I-Shyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107263/
https://www.ncbi.nlm.nih.gov/pubmed/30138456
http://dx.doi.org/10.1371/journal.pone.0202777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107263/
https://www.ncbi.nlm.nih.gov/pubmed/30138456
http://dx.doi.org/10.1371/journal.pone.0202777

Ejemplares similares